AstraZeneca Centre for Genomics Research enters partnership with DNAnexus

Collaborating to build informatics capability for world-class genomics initiative

The AstraZeneca’s Centre for Genomics Research (CGR) has today announced a collaboration with DNAnexus, Inc., the global leader in genome informatics and data management.

AstraZeneca’s world-class genomics initiative, launched in 2016 and led by Professor David Goldstein, focuses on samples donated by patients in clinical trials for research into human health. With dramatic advances in genomics technology, AstraZeneca can combine the full genome sequence from these patients with extensive clinical and drug response data from clinical trials. This insight is being combined with genomic information from collaboration partners in a bespoke database to apply the knowledge gained from an unprecedented two million genomes comprehensively across the entire research and development pipeline.

By working together with DNAnexus, AstraZeneca can leverage their secure cloud-based platform to analyse a massive volume of raw sequencing data rapidly and economically, enabling the processing of samples from thousands of patients per week and the sharing of data easily and safely with collaborators around the world.  

 


“Investing in genomics is critical to the continued innovation here at AstraZenecaThe DNAnexus platform offers a secure, scalable solution that will support our ambitious goal; to analyse two million genomes to help us better understand the underlying causes of disease. We look forward to working with DNAnexus and the support of their expertise in computing and bioinformatics to advance the future of personalised healthcare, ultimately to develop the most innovative and impactful treatments for patients.” 

Ruth March, Vice-President Personalised Healthcare and Biomarkers, AstraZeneca

 

“AstraZeneca is making significant strides towards changing the future of research and development across multiple disease areas, and we are excited to work with our partner to help build their drug discovery and development solution.” 

Richard Daly, Chief Executive Officer of DNAnexus
 

About Genomics

Genomics is the study of the genome, a double string of DNA which carries all the genes necessary to make and operate an organism. Although most of the information contained in the genome is the same between all individuals, there are many small differences which scientists believe can combine with environmental influences to cause common diseases such as diabetes, asthma or cancer.  Studying genomes across large populations allows us to more accurately pinpoint these differences and to develop new treatments that combat unwanted abnormalities in gene function which give rise to disease.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

About DNAnexus

DNAnexus combines expertise in computing and bioinformatics to create the global network for genomics, operating in North America, Europe, Asia-Pacific (including China), South America, and Africa. The secure, scalable, and collaborative DNAnexus Platform helps thousands of researchers across a spectrum of industries – biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia – accelerate their genomics programs globally. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.

tags

  • Partnering
  • Science